HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Says No To Street Drug Alternatives Posing As Supplements

This article was originally published in The Rose Sheet

Executive Summary

The agency warns Arco Globus Trading LLC to immediately stop marketing purported dietary supplements that it promotes as alternatives to illicit street drugs, including one with an active pharmaceutical antihistamine. The firm's Legal Lean Syrup and Coco Loko are unapproved and misbranded new drugs, the agency says.

You may also be interested in...



Sparq's Vitamin Vapor Inhalation Product Could Spark Regulatory Interest

Vitamin Air is so novel, it could get FDA's attention for misbranding as a supplement and being an unapproved new drug. Sparq says it's not an electronic cigarette because there's no nicotine in formulations it offers in products that resemble early-edition e-cigarettes. But it is a dietary supplement because each one is a mixture of vitamins, minerals and supplements plus natural flavors and glycerin so the formulations heat into vapor that is inhaled, the firm says.

Athlete's Foot Firm Kicks Back On NAD Finding That Brand Is A Fungal Claim

Kramer Laboratories' claims for Fungi-Nail athlete's foot product referred to FDA and FTC after it refuses to comply with NAD's recommendation to modify the name. The firm, which agreed to modify packaging and commercial claims, was warned by FDA about the brand in 2005.

Athlete's Foot Firm Kicks Back On NAD Finding That Brand Is A Fungal Claim

Kramer Laboratories' claims for Fungi-Nail athlete's foot product referred to FDA and FTC after it refuses to comply with NAD's recommendation to modify the name. The firm, which agreed to modify packaging and commercial claims, was warned by FDA about the brand in 2005.

Related Content

Topics

UsernamePublicRestriction

Register

RS121368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel